NextCure, Inc.
NXTC · XNASCIK 1661059fmd_14TYQFF9Z7E9Q6ETNE6TP43B57Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 6 | 22 | – | – | – | – | – |
| Research and development | 20 | 34 | 47 | 50 | 54 | 48 | 41 | 45 |
| Total operating expenses | 23 | 44 | 64 | 71 | 76 | 68 | 60 | 58 |
| Operating income | (23) | (37) | (41) | (71) | (76) | (68) | (60) | (58) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 4 | 5 | 1 | 1 | 5 | 4 | 2 |
| Income tax expense | – | – | – | – | – | – | – | 0 |
| Net income | (23) | (34) | (37) | (69) | (75) | (63) | (56) | (56) |